We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.79 | -0.62% | 127.47 | 128.48 | 127.18 | 128.11 | 6,221,929 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Shares of Pandion Therapeutics Inc. more than doubled in premarket trading Thursday after the clinical-stage biotechnology company agreed to be acquired by drug giant Merck & Co. for $60 a share, or about $1.85 billion.
The deal represents a 134% premium to Wednesday's closing price of $25.63 for Pandion, which went public last July at $18 a share.
Pandion shares rose as high as $27.75 on July 17, the company's first day of trading, but haven't reached that level since.
Pandion shares were recently up 132% to $59.44 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 25, 2021 09:13 ET (14:13 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
